113 related articles for article (PubMed ID: 35926819)
21. PALB2 self-interaction controls homologous recombination.
Buisson R; Masson JY
Nucleic Acids Res; 2012 Nov; 40(20):10312-23. PubMed ID: 22941656
[TBL] [Abstract][Full Text] [Related]
22. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
[TBL] [Abstract][Full Text] [Related]
23. Functional characterization of 84 PALB2 variants of uncertain significance.
Wiltshire T; Ducy M; Foo TK; Hu C; Lee KY; Belur Nagaraj A; Rodrigue A; Gomes TT; Simard J; Monteiro ANA; Xia B; Carvalho MA; Masson JY; Couch FJ
Genet Med; 2020 Mar; 22(3):622-632. PubMed ID: 31636395
[TBL] [Abstract][Full Text] [Related]
24. Breast cancer proteins PALB2 and BRCA2 stimulate polymerase η in recombination-associated DNA synthesis at blocked replication forks.
Buisson R; Niraj J; Pauty J; Maity R; Zhao W; Coulombe Y; Sung P; Masson JY
Cell Rep; 2014 Feb; 6(3):553-64. PubMed ID: 24485656
[TBL] [Abstract][Full Text] [Related]
25. The Role of PALB2 in the DNA Damage Response and Cancer Predisposition.
Nepomuceno TC; De Gregoriis G; de Oliveira FMB; Suarez-Kurtz G; Monteiro AN; Carvalho MA
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28858227
[TBL] [Abstract][Full Text] [Related]
26. A Short BRCA2-Derived Cell-Penetrating Peptide Targets RAD51 Function and Confers Hypersensitivity toward PARP Inhibition.
Trenner A; Godau J; Sartori AA
Mol Cancer Ther; 2018 Jul; 17(7):1392-1404. PubMed ID: 29654063
[TBL] [Abstract][Full Text] [Related]
27. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.
Xia B; Sheng Q; Nakanishi K; Ohashi A; Wu J; Christ N; Liu X; Jasin M; Couch FJ; Livingston DM
Mol Cell; 2006 Jun; 22(6):719-729. PubMed ID: 16793542
[TBL] [Abstract][Full Text] [Related]
28. Roles for APRIN (PDS5B) in homologous recombination and in ovarian cancer prediction.
Couturier AM; Fleury H; Patenaude AM; Bentley VL; Rodrigue A; Coulombe Y; Niraj J; Pauty J; Berman JN; Dellaire G; Di Noia JM; Mes-Masson AM; Masson JY
Nucleic Acids Res; 2016 Dec; 44(22):10879-10897. PubMed ID: 27924011
[TBL] [Abstract][Full Text] [Related]
29. EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases.
Cousineau I; Belmaaza A
Mol Genet Genomics; 2011 Apr; 285(4):325-40. PubMed ID: 21409565
[TBL] [Abstract][Full Text] [Related]
30. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
Smith MA; Hampton OA; Reynolds CP; Kang MH; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Wu J; Kurmasheva RT; Wheeler DA; Houghton PJ
Pediatr Blood Cancer; 2015 Jan; 62(1):91-8. PubMed ID: 25263539
[TBL] [Abstract][Full Text] [Related]
31. Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.
Biswas K; Das R; Eggington JM; Qiao H; North SL; Stauffer S; Burkett SS; Martin BK; Southon E; Sizemore SC; Pruss D; Bowles KR; Roa BB; Hunter N; Tessarollo L; Wenstrup RJ; Byrd RA; Sharan SK
Hum Mol Genet; 2012 Sep; 21(18):3993-4006. PubMed ID: 22678057
[TBL] [Abstract][Full Text] [Related]
32. Exploring the link between MORF4L1 and risk of breast cancer.
Martrat G; Maxwell CM; Tominaga E; Porta-de-la-Riva M; Bonifaci N; Gómez-Baldó L; Bogliolo M; Lázaro C; Blanco I; Brunet J; Aguilar H; Fernández-Rodríguez J; Seal S; Renwick A; Rahman N; Kühl J; Neveling K; Schindler D; Ramírez MJ; Castellà M; Hernández G; ; Easton DF; Peock S; Cook M; Oliver CT; Frost D; Platte R; Evans DG; Lalloo F; Eeles R; Izatt L; Chu C; Davidson R; Ong KR; Cook J; Douglas F; Hodgson S; Brewer C; Morrison PJ; Porteous M; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Roversi G; Barile M; Viel A; Pasini B; Ottini L; Putignano AL; Savarese A; Bernard L; Radice P; Healey S; Spurdle A; Chen X; Beesley J; ; Rookus MA; Verhoef S; Tilanus-Linthorst MA; Vreeswijk MP; Asperen CJ; Bodmer D; Ausems MG; van Os TA; Blok MJ; Meijers-Heijboer HE; Hogervorst FB; ; Goldgar DE; Buys S; John EM; Miron A; Southey M; Daly MB; ; ; Harbst K; Borg A; Rantala J; Barbany-Bustinza G; Ehrencrona H; Stenmark-Askmalm M; Kaufman B; Laitman Y; Milgrom R; Friedman E; Domchek SM; Nathanson KL; Rebbeck TR; Johannsson OT; Couch FJ; Wang X; Fredericksen Z; Cuadras D; Moreno V; Pientka FK; Depping R; Caldés T; Osorio A; Benítez J; Bueren J; Heikkinen T; Nevanlinna H; Hamann U; Torres D; Caligo MA; Godwin AK; Imyanitov EN; Janavicius R; ; Sinilnikova OM; Stoppa-Lyonnet D; Mazoyer S; Verny-Pierre C; Castera L; de Pauw A; Bignon YJ; Uhrhammer N; Peyrat JP; Vennin P; Ferrer SF; Collonge-Rame MA; Mortemousque I; McGuffog L; Chenevix-Trench G; Pereira-Smith OM; Antoniou AC; Cerón J; Tominaga K; Surrallés J; Pujana MA
Breast Cancer Res; 2011 Apr; 13(2):R40. PubMed ID: 21466675
[TBL] [Abstract][Full Text] [Related]
33. Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains.
Park D; Shakya R; Koivisto C; Pitarresi JR; Szabolcs M; Kladney R; Hadjis A; Mace TA; Ludwig T
PLoS One; 2019; 14(12):e0226714. PubMed ID: 31877165
[TBL] [Abstract][Full Text] [Related]
34. Fanconi anemia complementation group D2 (FANCD2) functions independently of BRCA2- and RAD51-associated homologous recombination in response to DNA damage.
Ohashi A; Zdzienicka MZ; Chen J; Couch FJ
J Biol Chem; 2005 Apr; 280(15):14877-83. PubMed ID: 15671039
[TBL] [Abstract][Full Text] [Related]
35. A genetic screen identifies BRCA2 and PALB2 as key regulators of G2 checkpoint maintenance.
Menzel T; Nähse-Kumpf V; Kousholt AN; Klein DK; Lund-Andersen C; Lees M; Johansen JV; Syljuåsen RG; Sørensen CS
EMBO Rep; 2011 Jul; 12(7):705-12. PubMed ID: 21637299
[TBL] [Abstract][Full Text] [Related]
36. Heterozygous PALB2 c.1592delT mutation channels DNA double-strand break repair into error-prone pathways in breast cancer patients.
Obermeier K; Sachsenweger J; Friedl TW; Pospiech H; Winqvist R; Wiesmüller L
Oncogene; 2016 Jul; 35(29):3796-806. PubMed ID: 26640152
[TBL] [Abstract][Full Text] [Related]
37. PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks.
Metzger MJ; Stoddard BL; Monnat RJ
DNA Repair (Amst); 2013 Jul; 12(7):529-34. PubMed ID: 23684799
[TBL] [Abstract][Full Text] [Related]
38. An
Myers SH; Poppi L; Rinaldi F; Veronesi M; Ciamarone A; Previtali V; Bagnolini G; Schipani F; Ortega Martínez JA; Girotto S; Di Stefano G; Farabegoli F; Walsh N; De Franco F; Roberti M; Cavalli A
Eur J Med Chem; 2024 Feb; 265():116114. PubMed ID: 38194775
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
[TBL] [Abstract][Full Text] [Related]
40. A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor.
Rodrigue A; Margaillan G; Torres Gomes T; Coulombe Y; Montalban G; da Costa E Silva Carvalho S; Milano L; Ducy M; De-Gregoriis G; Dellaire G; Araújo da Silva W; Monteiro AN; Carvalho MA; Simard J; Masson JY
Nucleic Acids Res; 2019 Nov; 47(20):10662-10677. PubMed ID: 31586400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
